Although induction of tumor vascular infarction by tTF fusion proteins leads to the significant regression of malignant tumors, and could even bear curative potential as single therapies13, complete elimination of tumors often fails due to induction of incomplete thrombosis and the systemic toxicity that is reported for tTF fusion proteins at the higher doses14. The gene discussed is RHOH; the disease is cancer.